King Laboratories

Pharmaceutical manufacturing and research are conducted by King Laboratories in healthcare sectors, focusing on generics, oncology, and respiratory therapies across global markets.

About King Laboratories

King Laboratories is a Healthcare company. Pharmaceutical manufacturing and research are conducted by King Laboratories in healthcare sectors, focusing on generics, oncology, and respiratory therapies across global markets. Its Indian entity King Laboratories Private Limited reported revenue of β‚Ή52.8 Lakh. King Laboratories offers products and services including Generic Drugs and Oncology Therapies. Its focus areas include Manufacturing, Generic Drugs, Formulations and Parenteral and Pharmaceuticals.

Company details

King Laboratories is recognized as a research-based pharmaceutical entity that operates with offices in over 50 countries and manufacturing facilities in four nations, where advanced therapies for dermatology, oncology, and respiratory conditions are developed to improve patient quality of life globally. Investments in research and development, including 6-7 of turnover and over 1,00,000 sq ft of dedicated space, are utilized by a team of 550 scientists to create generics, biosimilars, and parenteral products. Accreditations from international regulatory bodies are held by the company, ensuring compliance and a competitive edge in the generic market, while environmental health and safety standards are maintained through ongoing resource allocation. This structure supports a vertically-integrated approach across the pharmaceutical value chain, fostering innovation in differentiated medicines.

  • Sectors
    Healthcare
  • Email
    β€’β€’β€’β€’β€’β€’β€’β€’
  • Social Facebook
  • Legal Name King Laboratories Private Limited
  • Date of Incorporation 30 May, 2013
  • Jurisdiction Srinagar, Jammu and Kashmir, India
Key Metrics
  • Indian entity revenue
    ₹52.8 Lakh

    FY 2025 · +296% YoY

  • Indian entity net profit
    ₹92,119

    FY 2025 · 2% margin

  • Indian entity EBITDA
    ₹4.1 Lakh

    FY 2025 · 8% margin

Products & Services of King Laboratories

King Laboratories offers a comprehensive portfolio of products and services, including Generic Drugs and Oncology Therapies.

Generic Drugs
Pharmaceuticals

Generic drugs are manufactured by King Laboratories for major therapeutic segments, covering dosage forms like oral solids and powders, with a focus on vertical integration and global distribution.

Oncology Therapies
Specialty Drugs

Oncology therapies are developed by King Laboratories as advanced treatments for enriching patient lives, including biosimilars and formulations that are supported by research centers worldwide.

Board of directors of King Laboratories Private Limited (King Laboratories)

King Laboratories Private Limited is the primary company behind King Laboratories. The board of King Laboratories Private Limited currently have 2 directors; the longest-serving is Bhat Rouf Ahmad, appointed in 2013.

DirectorDesignationAppointedTenureEntity
Bhat Rouf Ahmad
DIN 06589185
Director30 May 201313 yrs 5 moKing Laboratories Private Limited
Taslim Arif Dar
DIN 06589175
Managing Director30 May 201313 yrs 5 moKing Laboratories Private Limited

Financials of King Laboratories

Figures of King Laboratories Private Limited, the primary company behind King Laboratories, for FY 2025. Revenue was ₹52.8 Lakh (+296% year on year). Net profit was ₹92,119 (2% margin). EBITDA was ₹4.1 Lakh (8% margin). Revenue has grown at a compounded annual rate of -9% over three years and +2% over five years.

  • ₹52.8 LakhRevenue · FY 2025 · +296% YoY
  • ₹92,119Net profit · 2% margin
  • ₹4.1 LakhEBITDA · 8% margin
  • ₹7 LakhPaid-up capital
  • -9%Revenue CAGR, 3 years
  • +2%Revenue CAGR, 5 years

Balance sheet, profit and loss, cash flow and ratios of King Laboratories Private Limited are on its company page.

Premium access

Detailed financial statements for King Laboratories

Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.

  • Statement rows
  • Financial ratios
  • Five-year trends
  • Downloads

Verified entity values are shown only after access is granted.

Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track β€” from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • βœ“
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • βœ“
    Full access to every database India & global coverage, advanced filters and rich profile details
  • βœ“
    Always-on access from your team account Single premium plan for everything you see on the portal

Frequently Asked Questions about King Laboratories

The primary company behind King Laboratories, King Laboratories Private Limited, reported revenue of β‚Ή52.8 Lakh for FY 2025, up 296% year on year.

King Laboratories is recognized as a research-based pharmaceutical entity that operates with offices in over 50 countries and manufacturing facilities in four nations, where advanced therapies for dermatology, oncology, and respiratory conditions are developed to improve patient quality of life globally. Investments in research and development, including 6-7 of turnover and over 1,00,000 sq ft of dedicated space, are utilized by a team of 550 scientists to create generics, biosimilars, and parenteral products. Accreditations from international regulatory bodies are held by the company, ensuring compliance and a competitive edge in the generic market, while environmental health and safety standards are maintained through ongoing resource allocation. This structure supports a vertically-integrated approach across the pharmaceutical value chain, fostering innovation in differentiated medicines.

King Laboratories offers Generic Drugs and Oncology Therapies.

King Laboratories operates through King Laboratories Private Limited.

The legal entities of King Laboratories currently have 2 directors, including Bhat Rouf Ahmad, Taslim Arif Dar.

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available